durvalumab,sorafenib,tremelimumab
pfizer,astrazeneca
['tremelimumab', 'durva', 'hcc', 'sorafenib', 'himalaya']
4-yr os update from the phs 3 himalaya trial of tremelimumab + durvalumab in hcc at #wcgic2023 excellent long-term survival data for stride 4-yr os rate of 19% (unprecedented in hcc) long-term os observed in relevant subgroups, incl. pts with non-viral liver disease 
Physician-scientist, focused on translational research in hepatobiliary cancer and precision oncology